Australian startup Eden Brew has secured US GRAS clearance for its cow-free casein and is launching a $20M Series B as it pivots from branded dairy to supplements and food fortification.
Australian precision fermentation startup Eden Brew has cleared a key US regulatory hurdle for its cow-free casein protein, but the more telling development is where the company plans to sell it: not the dairy aisle, but the supplements shelf. The pivot, shared with Green Queen on the sidelines of the Future Food-Tech Conference in San Francisco, is a quiet admission that animal-free dairy's path to consumers runs through nutrition products first, mass-market groceries later.
Eden Brew self-affirmed its recombinant beta-casein protein as Generally Recognized as Safe (GRAS), founder and CEO Jim Fader told Green Queen. The company now plans to notify the FDA of its GRAS conclusion, a meaningful step given that the self-determination pathway may soon face tighter scrutiny.
The startup filed its application with Food Standards Australia New Zealand (FSANZ), and the legislated timeline means it could receive approval in its home market later this year. According to the company, Eden Brew is progressing through the FSANZ approval process, with a public consultation phase upcoming.
But regulatory wins only matter if there's a viable commercial path, and Eden Brew has reconsidered what that path looks like. The startup originally planned to sell milk-without-the-cow consumer products. It is now targeting the supplements and food fortification market first.
The reason comes down to what casein actually does. Cow's milk contains four casein proteins that self-assemble into micelles, which are spherical structures with significant carrying capacity for calcium, phosphorus and other nutrients that they release slowly. Eden Brew's DeepForte platform recreates these micelles and can fortify them with iron, magnesium and zinc, which conventional dairy struggles to deliver effectively.
Fader indicated that the company's approach offers dairy functionality while enabling fortification capabilities that conventional dairy cannot easily achieve. The company has signed an offtake agreement with an Australian supplements business and is building out its pipeline in that sector.
To fund the next phase, Eden Brew is launching a Series B round, on top of funding already raised from private and public investors. First production will run in a tank yielding around one tonne of finished product, with plans to scale production to close to four tonnes of protein per year. The company aims to reach price parity with conventional dairy.
The fundraise lands in a tough market. Fermentation startups have seen reduced investment recently, with the bulk of venture capital flowing toward AI. Eden Brew's pitch leans on customer offtakes, positive unit economics and a capital-light model that outsources manufacturing rather than building its own plant.
The company is not alone in working on recombinant casein. AgFunderNews recently reported that Perfect Day expects its Gujarat, India facility to begin operations in the second half of 2026, ramping into 2027, while a broader field including New Culture, Standing Ovation, Formo and others continues to develop casein via precision fermentation.
Eden Brew's decision to enter through supplements rather than the dairy aisle is a clear-eyed acknowledgment of where this technology can win first. Branded plant-based and animal-free dairy products have faced a brutal couple of years on shelf. Specialist nutrition, with its higher margins and less price-sensitive buyers, offers a more forgiving entry point for a company still scaling. The company envisions eventual mass-market applications like iron-fortified cheese slices for children's lunchboxes, but reaching those shelves will depend on cost curves the entire sector is still trying to bend.
